Comparison of the mechanisms of action of antidepressants and their side effects
DOI:
https://doi.org/10.12775/JEHS.2020.10.08.030Keywords
depression, mental disorders, antidepressants, side effectsAbstract
Introduction: There are 4 groups of LPs divided according to the mechanism of action. They act on the brain by modulating monoaminergic systems, causing a series of side effects such as insomnia, sedation, anxiety, and a problem of a sexual nature. By appropriately selecting the drug and its dose, the negative effects of the therapy can be avoided.
Aim : Comparison of the mode of action of a drug from a given group of antidepressants and description of its side effects.
State of knowledge : An example from the first group of drugs with a receptor mechanism of action is trazodone - it acts on many receptors. The combined effect of the drug on all three receptors will significantly improve sleep in all its phases. It is as effective a drug as TLPD, and due to the lack of anticholinergic and cardiotoxic effects, it has a better tolerance and safety profile. It works quickly and improves sleep parameters, which is responsible for faster improvement of the patient's mental state. An example of a drug from the second group of drugs with a different mechanism of action is agomelatine. It is a synthetic analog of melatonin. The simultaneous agonist action on one receptors and antagonist action on the other causes a number of changes in the CNS, which are responsible for the antidepressant effect. The effects of the treatment can be seen after 2 weeks of use. The drug of the third groupneurotransmitter reuptake inhibitorsthere is bupropion. It intensifies the dopaminergic transmission. It does not disturb the sexual sphere, but increases insomnia as a side effect.
Summary : By selecting the appropriate LP and its dose, side effects can be avoided.
References
Kostowski W. Współczesne kierunki badań nad patomechanizmem stresu i depresji i ich znaczenie w kształtowaniu poglądów na działanie leków przeciwdepresyjnych. Psychiatria, 2004; 2 (1): 63-71.
https://www.depresjaza.pl/leki (13.08.2020)
Burke MJ, Preskorn SEE. Short-term treatment of mood disorders with standard antidepressants. W: Bloom FE, Kupfer DJ, red, Psychopharmacology: The fourth generation of Progress. New York: Raven Press; 1995, s. 1053-1065.
Riblet LA, Taylor DP. Pharmacology and neurochemistry of trazodon. J. Clin. Psychopharmacol. 1981; 1 (supl): 17-22.
Stahl SM. Mechanism of action of trazodon: a multifunctional drug. CNS Spectr. 2009; 14: 536-546.
Oberndorfer S, Saletu-Zychlarz G, Saletu B. Effects of selective serotonin reuptake inhibitors on objective and subjective sleep quality. Neuropsychobiol. 2000; 42: 69-81.
Le Bon O. Contribution of sleep research to the development of New antidepressant. Dialog. Clin. Neurosc. 2005; 7: 305-313.
Shigemoto Y, Fujii Y, Shinomiya K, Kamei C. Participation of histaminergic H1 and noradrenergic alpha 1 receptors in orexin A-induced wakefulness in rats. Brain Res. 2004; 1023: 121-125.
Landowski J. Wybór leku przeciwdepresyjnego. Dysk. Depr. 2001; 10: 2-11.
Stahl SM. Mechanism of action of trazodon: a multifunctional drug. CNS Spectr. 2009; 14: 536-546.
Monteleone P, Delrio G. Pharmacocinetic and pharmacodynamic characteristics of a controlled release formulation of trazodone versus the conventional formulation in healthy volunteers. Ital. J. Neurol. Sc. 1993; 14: 443-449.
Haria M, Fitton AS, McTavish D. Trazodone. A review of its pharmacology, therapeutics use in depression and therapeutic potential in other disorders. Drugs Aging 1994; 4: 331-335.
Mann J, Georgotas A, Newton R, Gerschon S. A controlled study of trazodone, imipramine and placebo in outpatients with endogenous depression. J. Clin. Psychopharmacol. 1981; 42 (1): 75-80.
Carney PA, Healy D, Leonard BE. A double-blind study to compare trazodone with amitryptyline in depressed patients. The role of trazodone in antidepressant therapy: safety and clinical efficacy. Psychopathol. 1984; 17 (supl. 2): 37-38.
Poldinger W. Experiences with doxepine and trazodone in the therapy with outpatients suffering from depression. Psychopathol. 1984; 17: 30-36.
Cubała W, Landowski J. Spektrum zastosowań klinicznych trazodonu. Psychiatr. 2011; 8: 1-6.
Beasley CM Jr, Dornseif BE, Pultz JA, Bosomworth JC, Sayler ME. Fluoxetin versus trazodone : Efficacy and activating-sedating effects. J. Clin. Psychiatry 1991; 52: 294-299.
Fabre LF Jr. United States experience and perspective with trazodone. Clin. Neuropharmacol. 1989; 12 (supl. 1): 11-17.
Le Strat Y, Gorwood P. Agomelatine, an innovative pharmacological response to unmet needs. J. Psychopharmacol. 2008; 22: 4-8.
Papp M, Litwa, Gruca P, Mocaer E. Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav. Pharmacol. 2006; 17: 9-18.
Stahl SM. Novel mechanizm of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism. Int. J. Neuropsychopharmacol. 2007; 10 (5): 575-578.
Millan MJ, Gobert A, Lejeune F i wsp. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activiy of trontocortical dopaminergic and adrenergic pathways. J. Pharmacol. Exp. Ther. 2003; 306: 954-964.
Hanoun N, Mocaer E, Boyer PA, Hamon M, Lanfumey L. Differental effects of the novel antidepressant agomelatine (S20098) versus fluoxetine on 5-HT1A receptors in the rat brain. Neuropharmacology 2004; 47: 515-526.
Zupancic M, Guilleminault C. Agomelatine: a preliminary review of a New antidepressant. CNS Drugs 2006; 20 (12): 981-992.
Gressens P, Schwedimann L, Husson I i wsp. Agomelatine, a melatonin receptor agonist with 5-HT2C receptor antagonist properties, protects the developing murine white matter against excitotoxicity. Eur. J. Pharmacol. 2008, 588: 58-63.
Hale A, Coral RM, Mencacci C, Ruiz JS, Severo CA, Gentil V. Superior
antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, doubleblind study. Int. Clin. Psychopharmacol. 2010, 25: 305-314.
European Medicine Agency: Evaluation of medicines for human use – CHMP Assessment Report for Valdoxan, http://www.emea.europa.eu/humandocs/PDFs/EPAR/valdoxan/H-915-en6.pdf. (6.08.2020)
Stahl SM, Fava M, Trivedi MH, Caputo A, Post A. Agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. 2010; 30: 135-144.
Dunlop BW, Nemerhoff CB. The role of dopamine in the pathophysiologiy of depression. Arch. Gen. Psychiatry 2007; 64: 327-337.
Learned-Coughlin SM, Bergstrom M, Savitcheva I, Ascher J, Schmith VD, Langstrom B. In vivo activity of bupropion at the human dopamine transporter as measures by positron emission tomography. Biol. Psychiatry 2003; 53: 800-805.
Panksepp J, Burgdorf J. The neurobiology of positive emotions. Neurosc. Biobehavior Rev. 2006; 30: 173-187.
Angs J. Sexual problems in health and depressed persons. Int. Clin. Psychopharmacol. 1998; (13) 1: 28-35.
Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clin. Ther. 2005; 27: 1685-1695.
Downloads
Published
How to Cite
Issue
Section
License
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 1117
Number of citations: 0